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Photodynamic therapy (PDT) is a novel approach in the treatment of carcino-
mas of the gastrointestinal tract. This review defines PDT, discusses means of
photosensitization and considers the mechanisms by which PDT causes cell
death ofthe target tissue while at the same time avoid damage to normal tissues.
Additional considerations include the time ofPDT application, activation ofthe
photosensitizer, effectiveness and toxicity ofPDT, potential need for additional
modalities of treatment and concludes with application ofPDT principals to the
early detection of malignancy. Data regarding the long term effectiveness of
PDT for digestive tract adenocarcinomas are lacking because this field is still in
its infancy.
WHAT IS PHOTODYNAMIC THERAPY?
Photodynamic therapy (PDT)b, a relatively new and potentially important form of
adjuvant treatment for cancers of the digestive tract, initially involves the preferential
accumulation of a photosensitizing compound by malignant tissues. Suitable photody-
namic sensitizers exhibit no spontaneous toxicity unless and until they are excited by light
at a wavelength corresponding to an absorbance band ofthe sensitzer. Excitation leads to
cellular destruction, primarily mediated by singlet oxygen [1-8]. This form of molecular
oxygen is toxic and results in both direct tumorcell kill as well as lethal effects due to vas-
cular occlusion. A number of reports indicate that PDT is effective in treating malignant
tumors in experimental animals. There also are an increasing number of preliminary
reports of PDT use for the treatment of human tumors, including carcinoma of the oral
cavity, esophagus, stomach, rectum, biliary tract, tracheobronchial tree, lung, skin, breast,
brain, bladder, female genital tract, Kaposi's sarcoma, retroperitoneal sarcomas, mesothe-
lioma and carcinomatosis ofthe peritoneal cavity [1, 9-24]. Previous treatment oftumors
with radiation therapy and/or chemotherapy does not appear to alter responsiveness to
PDT. Similarly, application ofPDT does not preclude the subsequent use ofradiation ther-
apy and/or chemotherapy.
PHOTOSENSITIZATION
There are two approaches to the administration ofphotosensitizers. One is exogenous
and involves administration of the photosensitizer intravenously and relies on selective
uptake ofthe drug by the target tissue, or tumor. The second is to rely on endogenous pho-
tosensitization whereby the target tissue converts a "precursor drug" into a photoreactive
compound.
a'To whom all correspondence should be addressed: David Fromm, M.D., Department of Surgery,
6C-University Health Center, 4201 St. Antoine, Detroit, MI 48201. Tel:. 313-745-8778; Fax: 313-
745-1873; E-mail: dfsurg@aol.com.
bAbbreviations: PDT, photodynamic therapy; ALA, 5-aminolevulinic acid; PpIX, protoporphyrin IX.
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Exogenous photosensitization:
The most frequently used exogenous sensitizer in clinical studies of PDT for gas-
trointestinal tumors is Photofrin, a somewhatpurified proprietary preparation of "hemato-
porphyrin derivative," a complex mixture of various porphyrin monomers, dimers and
polymers derived from mammalian blood. This photosensitizer, which is given intra-
venously, is efficacious. However, Photofrin can lead to anaphylactic reactions [23] and
prolonged photosensitization of normal skin. ("Photofrin" is used in this review to refer
both to hematoporphyrin derivative and Photofrin II).
Endogenous photosensitization:
An alternative approach to photosensitization of a cancer is the induction of a chem-
ical porphyria, a novel means whereby PDT is effective as a result of endogenous pro-
duction of the photosensitizer [25]. This involves the oral administration of 5-aminole-
vulinic acid (ALA), which is absorbed into the blood stream and converted by cellular
enzymes to protoporphyrin IX (PpIX). ALA is a naturally occurring five carbon amino
acid [26] and is the first committed intermediate in the heme biosynthetic pathway (which
occurs in mitochondria) [27]. This reaction has been observed in cultured cells, whole ani-
mals and selected tumors ofhumans. ALAper se is not a photosensitizer but rather its end
product, PpIX, is the photoreactive species.
By normal feedback control, heme inhibits the activity ofALA synthase, the first and
rate-limiting enzyme ofthe biosynthetic pathway, thereby preventing the cell from drown-
ing in an excess production of its own porphyrins. This negative feedback control can be
bypassed in certain types of malignant cells exposed to an excess amount of exogenous
ALA. TheALA is continuously metabolized by these cells, leading to an over-production
of several porphyrins, predominantly PpIX. Excess accumulation ofPpIX occurs because
of the enzyme make up of certain malignant cells. The latter have a relatively low activi-
ty offerrochelatase [28-32], which catalyzes the insertion of an iron atom into PpIX. This
forms heme (which is not photoreactive), thereby inhibiting photodynamic activity.
Another factor leading to augmented PpIX synthesis is the increased activity of the rate
limiting enzyme porphobilinogen deaminase in various malignant tissues [1, 33-35].
Hepatic synthesis of PpIX from ALA is quite efficient and it is likely that there is subse-
quent transport of PpIX by the blood stream to peripheral sites. However, isolated cells
can synthesize PpIX upon exposure to ALA and PpIX is limited to a subcutaneous injec-
tion site ofALA in mice and humans [27, 36].
HOW DOES ACTIVATION OF THE PHOTOSENSITIZER KILL CELLS?
Photosensitizers exhibit a characteristic absorption spectrum. Upon irradiation of
cells containing the photosensitizer with a specific wave length of light corresponding to
the absorbance maxima of the sensitizer, the electronic configuration of the sensitizer is
raised to a higher energy level (excited state). This excess energy can be converted to heat,
to fluorescence emission, or via an intersystem crossing to the "triplet" state from which
energy can be transferred to oxygen in tissues. This results in the formation of "singlet"
molecular oxygen, a highly reactive, short-lived (half life: 10-6 sec) cytotoxic agent [37,
38]. The latter reacts with amino acids, unsaturated fatty acids and nucleic acids, result-
ing in cell damage [1]. Other reactive oxygen species can be formed (superoxide, hydro-
gen peroxide and the hydroxyl radical) [39-41], but PDT effects on tumor tissue appear
128Webber et al.: PDTand endogenous photosensitization 129
to be mediated largely by singlet oxygen [41, 42]. The yield ofsinglet oxygen depends on
the oxygen concentration in the tissues [43]. While cells exposed to ionizing radiation in
the absence of oxygen are 2-3 times less sensitive than cells exposed under aerated con-
ditions, isolated cells are completely insensitive to PDT in the absence of oxygen [43].
The nature ofcellular changes produced by PDT are also different than X-irradiation [6].
Cellular effects:
The oxidative injury mediated by PDT involves various subcellular targets. PDT
increases the expression ofstress proteins and heme-oxygenase (a rate limiting enzyme in
heme metabolism) as well as the release or increased production of eicosanoids, tumor
necrosis factor, interleukins, serotonin and histamine [44-47]. Depending on the photo-
sensitizer used, PDT can affect mitochondria and lysosomes, although lysosomal hydro-
lases are inactivated by the photochemical treatment before escaping the lysosomal com-
partment [48]. Photodamage can also be detected at the plasma and endoplasmic reticu-
lum membranes, and can affect DNA, resulting in the rapid initiation ofapoptosis [43, 49-
55, 56]. Photofrin appears to mediate oxidative stress through protein kinase-mediated
signal transduction pathway(s) to activate early response genes [57]. ALA-induced por-
phyrin formation is more specifically localized to the mitochondria ofcertain types ofnor-
mal and malignant cells in laboratory animals, and this includes mitochondria ofendothe-
lial cells oftumor tissue [28]. However, various photosensitizers act differently as a result
ofdifferent patterns of intracellular localization of the sensitizers [43], since singlet oxy-
gen reacts at its sites oforigin. The subcellular distribution ofsensitizers has been studied
mainly in in vitro systems, although it has been proposed that patterns of biodistribution
matter little with respect to in vivo effectiveness [44].
Vascular effects:
Eventual vessel occlusion seems to be a general phenomenon associated with PDT
using Photofrin [44]. The time frame that a decrease in blood occurs is variable, ranging
from within 10 sec to 10 min in experimental tumors [58, 59]. It is not clear if this range
is due to characteristics ofthe specific tumor model and/or technical features related to the
application of PDT. Nevertheless, phototoxicity from Photofrin appears to involve the
destruction of the tumor vasculature, an effect which appears to be selective, even in
regions oftumor where the photosensitizer concentration is similar to that in normal adja-
cent tissue [43]. Thus, the effect ofPhotofrin may be mainly an indirect one, derived from
the destruction ofthe tumor vasculature [60]. Vascular destruction itself, without any con-
tribution from direct tumor cell kill, can lead to cures of experimental tumors. Given the
importance of oxygen availability on phototoxicity, the rapid formation of hypoxic cells
resulting from vascular damage increases the likelihood that some tumor cells will escape
direct photodestruction [61, 62]. If a photodynamic agent has primarily vascular effects,
there is a theoretical disadvantage ofhypoxic, but still viable, cells persisting at the inter-
face of necrotic and surrounding well perfused regions [63].
A proposed advantage of chemically-induced porphyria with ALA is that the pho-
totoxic effect relies primarily on direct cell kill, whereas other photosensitizing agents
appear to rely more on vascular effects [64, 65-67]. However, it is becoming apparent
that ALA has definite vascular effects but the data are difficult to compare because of
the number of confounding technical variables involved in these studies. For example,
the vascular effects are related to the duration and intensity of the light source used to
activate PpIX derived from ALA [68, 69]. Adding to the controversy are magnetic reso-
nance spectroscopic studies suggesting that direct cellular damage from PDT per se
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and are mostly attributable to vascular damage [70]. If this is the case, it suggests that
cellular destruction caused by PDT occurs by a dual synergistic mechanism.
On the one hand, distinction between a direct cell killing effect and a vascular effect
of PDT may appear to be an academic argument, as long as destruction of the tumor
occurs. Hypoxic regions exist in many experimental tumors due to variability in vascular-
ization, yet PDT is still effective [71]. Thus, cell death may not occur immediately from
photodynamic effects, but later as a result of a local circulatory effect. On the other hand,
the distinction has importance to the technical aspects of PDT. The shift of cells into
hypoxia does not necessarily imply that they are protected from further PDT damage.
Hypoxia may be reversible, depending on light treatment dose and activating light frac-
tionation schemes that permit re-establishment of blood flow during short intervals (but
this may depend on the individual tumor, sensitizer dose, etc) [44]. Thus, reoxygenation
permits additional PDT treatment which might be more efficient in destroying remaining
viable tumor cells.
HOW CAN PDT AVOID DESTRUCTION OF NORMAL TISSUE?
Since ALA-induced PpIX is not completely specific for malignant tissue, there will
always be some PpIX-induced photosensitization of normal tissues. This effect is mainly
caused by the relatively slow conversion of PpIX to heme and might place normal tissues
at risk for photodestruction. However, such damage can be avoided by relying on bleach-
ing of the photosensitizer. ALA-induced PpIX is rapidly photobleached; that is, PpIX is
destroyed by auto-oxidation. Thus, a low concentration of tissue PpIX can be photo-
bleached before the photodynamic threshold for tissue damage occurs. This phenomenon
makes it possible to "overdose" the treatment field to get maximum light penetration with-
out causing serious damage to normal tissue. However, malignant cells will only be
destroyed if sufficient PpIX accumulates so that there is a loss of viability before photo-
bleaching can reduce the PpIX concentration to a non-toxic level [27, 64, 72, 73].
HOW SOON AFTER ADMINISTRATION OF ALA IS PDT APPLIED?
A very practical issue is knowing when the concentration of PpIX in the target tissue
reaches not only a sufficient level for PDT to be effective but also a level substantially
greater than the surrounding normal tissue. Our studies of actual tissue concentrations of
PpIX after administration ofALA indicate that the time of peak PpIX levels occurring in
both normal and malignant tissues can vary by several hours among patients [74]. The
importance of this observation is that it may explain why some adenocarcinomas of the
gastrointestinal tract appear to be unresponsive to PDT using ALA [8]. Serial measure-
ments of actual PpIX tissue concentrations prior to PDT treatment is impractical because
of the involved time for such determinations. However, advantage can be taken of the fact
that photosensitizers fluoresce. PpIX fluoresces to a salmon pink color in response to blue
light. In humans, it has been shown that more than 96 percent of fluorescing porphyrin
after administration ofALA is PpIX [13, 75].
Gross visualization ofporphyrin fluorescence does not always correlate with the actu-
al tissue concentrations [76]. This is related to tissue pigmentation, fluorescence quench-
ing and the lack of quantitative sensitivity of the human eye. However, changes in tissue
concentrations of PpIX can be quantitated in humans by applying spectrophotometric
methodology [77]. The advantage of the latter is that it offers a practical means for deter-
mining the most favorable time for starting PDT because relative changes in fluorescent
signals correlate with changes in tissue concentrations of PpIX [77]. At the time of
surgery, we use a sterile dual fiber optic cable (one fiber for delivery of blue activating
light and one fiber for detection of fluorescence) connected to a spectrophotofluorometer.
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Our studies withALA in humans indicate that significantly greaterconcentrations ofPpIX
occur in adenocarcinomas of the gastrointestinal tract than in skin, skeletal muscle,
intestinal muscle, mucosa and fat [74].
It is not yet known if the ratios between tumor and normal tissue concentrations can
be improved in humans with intravenously administeredALA, although experimental stud-
ies show that the temporal kinetics ofeither oral or intravenous administration are similar
[75]. Presently, oral intake ofALA by patients is preferable to intravenous administration,
because the latter requires buffering to avoid adverse side effects. ALA is also poorly sol-
uble in water and is chemically unstable at pH 7.4. However, there are several experimen-
tal ways to increase PpIX synthesis in response to ALA [22, 78], which may ultimately
become clinically applicable. Intravenous administration of pure PpIX is also presently
impractical because PpIX is only slightly soluble in water at physiological pH [27].
ACTIVATION OF THE PHOTOSENSITIZER
Porphyrins absorb light at several wavelengths, but the most effective excitation
wavelength is in the 405 nm (visible blue light) range. However, 630 nm (visible red light)
is most often used for PDT because of its greater penetration in tissues [10, 79, 80]. The
light source most often used to activate PpIX is a laser, not only because of its sharply
defined wavelength, but also because the light bundle of a laser shows little divergence,
making it possible to focus sharply. Specific laser photoactivation ofsensitized cells is not
one ofeither photocoagulation orphotothermal ablation (vaporization) [64, 81], but rather
like a switch to activate PpIX.
The optimal dose of light used to activate a photosensitizer in human cancers is not
known and consideration ofthis issue is complex. Light dose is expressed as the delivered
quantity (exposure dose) in J/cm2, but the absorbed dose depends on the spectrum of the
light source, irradiation geometry, depth in the tissue, light scattering in the tissue, con-
centration of the photosensitizer in the tissue, hemorrhage within the tumor as well as
other factors [82, 83], making the absorbed dose difficult to calculate.
The PDT response is dependent on both the drug concentration and the light dose
(conc*J/cm2) [72, 78, 84-86]. A "threshold" PDT dose must be exceeded for necrosis to
occur. Since porphyrins are degraded (bleached) by light, a weaker response occurs at low
drug concentrations. In order to obtain a PDT response at lower cellular drug concentra-
tions, the light exposure must be increased. If a proper photosensitizer dose is used, then
differential uptake by tumor should allow destruction of tumor and protection of normal
tissue even at very high light doses because the level of photosensitizer in normal tissue
would be below the photodynamic threshold for necrosis [73]. Thus there are at least 3
variables: degradation of the sensitizer (bleaching), differential tissue uptake, and thresh-
old effects.
There is also controversy concerning total light dose and cell kill; some investigators
have proposed that cell kill is proportional to the light dose which is independent of the
power of the laser [87, 88]. Others suggest that the effect of PDT is inversely related to
the strength of the light source [37, 89, 90], but this may be a characteristic of specific
tumor types.
IS PDT EFFECTIVE IN DESTROYING DIGESTIVE TRACT TUMORS?
There is no question that proper application of PDT results in destruction of adeno-
carcinomas of the digestive tract [7, 8, 24, 91]. However, it is only recently that PDT has
been systematically applied to these tumors and thus, necessary long term data relating to
effectiveness are not yet available. However, there are limits to PDT and the major limit-
ing factor is the depth of tumor kill.
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The depth of penetration of 630 nm light in tissue ranges from 0.2 to 2 cm [15, 22,
43, 92, 93]. The mean depth of destruction of rectal and sigmoid adenocarcinomas in
patients receiving Photofrin amounts to 0.6 cm with a range of 0.3 to 1.5 cm following
intraluminal insertion of an optical fiber 1 mm into the tumor [94]. Among factors that
limit light penetration are the presence of blood clot and necrosis within the tumor and
absorption of light by the photosensitizer itself (a phenomenon called "self-shielding").
These factors may also limit the effectiveness of an interstitial light delivery system in
which the laser light fibers are directly inserted into the tumor.
It appears that the main benefit ofPDT at present for gastrointestinal tumors may be
fourfold: 1) local control ofmicroscopic deposits remaining after what seems to be a cura-
tive resection; 2) removal ofrelatively small deposits remaining after debulking surgery;
3) primary treatment for small mucosal lesions; or 4) palliative treatment. While PDT is
not the stick of dynamite that everyone wishes to have available, it still may have an
important, albeit somewhat, limited role. More promising are newer experimental pho-
toreactive agents are sensitive to longer wavelengths oflight (> 660 nm), which will result
in deeper tissue penetration. An important aspect of using PDT for palliation is that PDT
can be repeated in multiple successive sessions.
TOXICITY OF PDT AND PHOTOSENSITIZERS
The toxicity ofPDT is site-specific, being dependent upon the organ being irradiated
and the selectivity of the photosensitizer for target tissue over normal tissue. A universal
and clinically important adverse effect of PDT is skin photosensitization that leads to sun
burns [11]. Most photosensitizing agents are not concentrated per se in the skin, but low
concentrations can be found in the skin for several weeks. For example, Photofrin cannot
be bleached sufficiently to achieve photoprotection of the skin [95]. Although the mean
duration of photosensitization with Photofrin injection is 3 months, true sunburns have
been observed as late as 9 months [9, 11]. In contrast, ALA-induced PpIX is almost com-
pletely cleared from human plasma by 72 hr oforal administration. An occasional patient
has been reported to develop mild cutaneous phototoxicity as late as 48 hr after receiving
ALA [91]. However, by keeping patients in subdued light for 48 hr, preventing exposure
to photodiode monitors (forexample, apulse oximeter) and filtering operating room lights
to prevent nonspecific photoactivation of PpIX, we have not observed any phototoxic
reactions after ALA administration.
An initial concern about administration ofALA is that it might mimic a genetic dis-
order of heme metabolism known as acute intermittent porphyria. This condition is char-
acterized by increased levels ofALA in plasma and cerebrospinal fluid. Clinical manifes-
tations include vomiting, tachycardia, abdominal pain, peripheral neuropathy and, to a
lesser extent, central neuropathy [97].Yet, there is minimal systemic dark toxicity (that is,
in the absence oflight) ofALA given orally. Except for mild nausea and vomiting, which
occurs in almost a quarter ofpatients after oral intake ofALA, these other manifestations
of porphyria have not been reported following ingestion of ALA. Experimental studies
show that highALA concentrations may lead to changes in behavior, cell membrane func-
tion as well as neuromuscular and spinal cord transmission. These effects have not been
observed in humans. No clinically significant renal, cardiac, hepatic, pulmonary or meta-
bolic adverse drug reactions have been reported in humans to date [11]. However, tran-
sient and variable abnormalities of liver function tests occur in about a third of patients
given ALA.
Ifthere is poor differential localization ofthe photosensitizer between malignant and
normal tissue, there exists the potential for unwanted tissue damage [91, 77]. This may be
more likely with the use of Photofrin than ALA, but there are also more clinical studies
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involving use of Photofrin. For example, esophageal strictures occurred in 35 percent of
patients who were given hematoporphyrin derivative as the photosensitizer for PDT
involving esophageal cancers [91]. We have not to date observed any clinically significant
unwanted tissue damage in patients who receiveALA and focal applications ofPDT with-
in the peritoneal cavity.
WILL PDT AVOID THE NEED FORADDITIONAL CANCER TREATMENT?
Nuclear damage and/or repair is not believed to be a dominant factor in PDT induced
cytotoxicity in cells sensitized with Photofrin [43]. However, PDT may cause indirect
damage to DNA, which might explain in part why different sensitizers and cell lines
behave so differently with respect to induction of mutations [43]. There has been some
suggestions that mutagenesis may occur as a result of PDT [44] and incomplete tumor
destruction by PDT may lead to clonal emergence of more malignant cells [96].
Spontaneous mutation of tumors may also make them resistant to PDT. A case report of
multiple cutaneous metastases from a breast cancer indicated that all but one site were
sensitive to PDT using hematoporphyrin derivative [98].
APPLICATION OF PRINCIPALS OF PDT TO TUMOR DETECTION
Another use for chemically-induced porphyria with ALA relates to the detection of
malignant tissues by fluorescence. Excitation of a photosensitizer by an incident photon
produces re-emission of a fluorescent photon, which can be used to localize the reaction
[11]. This might enable detection ofmetastases not ordinarily evident [10]. There appears
to be a correlation between the presence of local tumor and local fluorescence. Success
has been reported in examining potential treatment fields exposed to Photofrin using UV
light [10, 17, 27]. Gross detection of fluorescence using UV light works with Photofrin
andALA-induced PpIX, but this requires subjective assessment using the eye and the UV
spectrum does not include the peak excitation wavelength (410 nm) of PpIX [99]. More
sensitive detection of PpIX can be accomplished in patients using spectrophotofluoro-
metric technology using specific excitation wave lengths [56]. Application of this princi-
ple may ultimately lead to a relatively simple method for detecting tumor spread and
directing site specific, rather than random, biopsies in order to more accurately determine
the stage ofthe tumor.
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